Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2011

01-06-2011 | Research

Involvement of c-Ski Oncoprotein in Carcinogenesis of Cholangiocacinoma Induced by Opisthorchis viverrini and N-nitrosodimethylamine

Authors: Thidarut Boonmars, Zhiliang Wu, Sirintip Boonjaruspinyo, Anucha Puapairoj, Butsara Kaewsamut, Isao Nagano, Somchai Pinlaor, Puangrat Yongvanit, Orasa Wonkchalee, Amornrat Juasook, Pakkayanee Sudsarn, Tuanchai Srisawangwong

Published in: Pathology & Oncology Research | Issue 2/2011

Login to get access

Abstract

Opisthorchiasis is the major public health problem in the endemic areas of Thailand and Laos because Opisthorchis viverrini infection causes serious hepatobiliary diseases including CCA. The molecular mechanism of the CCA carcinogenesis induced by the infection remains obscure. To reveal the potential genes and signaling pathways to involve in the carcinogenesis, the present study investigated the expression of c-Ski, an oncogene, and two TGF-β signaling pathway relative genes, TGF-β and Smad4, during the development of CCA induced by O. viverrini infection in hamster model, and in human opisthorchiasis associated CCA. The results showed that the expression of c-Ski gene was greatly up-regulated during the carcinogenesis of CCA in hamster model. The overexpression of c-Ski was confirmed by immunohistological staining result which showed the increased expression of c-Ski protein in cytoplasm of the epithelial lining of hepatic bile ducts. Moreover, the immunohistological staining of the specimens of human opisthorchiasis associated CCA revealed the up-regulated expression of c-Ski and Smad4 proteins in the cytoplasm of the epithelial lining of hepatic bile ducts and stomal fibrosis respectively. The expression of TGF-β and Smad4 were up-regulated, which expression kinetics was time-dependent of CCA development. These results suggest that c-Ski is likely involved in the carcinogenesis of CCA induced by O. viverrini infection through regulating TGF-β signaling pathway.
Literature
1.
IARC (1994) Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risk Chem Hum 61:121–175
2.
Sithithaworn P, Haswell-Elkins M (2003) Epidemiology of Opisthorchis viverrini. Acta Trop 88:187–194PubMedCrossRef
3.
4.
Thamavit W, Kongkanuntn R, Tiwawech D, Moore MA (1987) Level of Opisthorchis infestation and carcinogen dose-dependence of cholangiocarcinoma induction in Syrian golden hamsters. Virchows Arch B Cell Pathol Incl Mol Pathol 54:52–58PubMedCrossRef
5.
Thamavit W, Pairojkul C, Tiwawech D et al (1993) Promotion of cholangiocarcinogenesis in the hamster liver by bile duct ligation after dimethylnitrosamine initiation. Carcinogenesis 14:2415–2417PubMedCrossRef
6.
Thamavit W, Pairojkul C, Tiwawech D, Shirai T, Ito N (1994) Lack of promoting effect of proline on bile duct cancer development in dimethylnitrosamine-initiated hamster livers. Teratog Carcinog Mutagen 14:169–174PubMedCrossRef
7.
Li Y, Turck CM, Teumer JK, Stavnezer E (1986) Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene. J Virol 57:1065–1072PubMed
8.
Colmenares C, Stavnezer E (1989) The ski oncogene induces muscle differentiation in quail embryo cells. Cell 59:293–303PubMedCrossRef
9.
Fumagalli S, Doneda L, Nomura N, Larizza L (1993) Expression of the c-Ski proto-oncogene in human melanoma cell lines. Melanoma Res 3:23–27PubMedCrossRef
10.
Pelzer T, Lyons GE, Kim S, Moreadith RW (1996) Cloning and characterization of the murine homolog of the sno proto-oncogene reveals a novel splice variant. Dev Dyn 205:114–125PubMedCrossRef
11.
Atanasoski S, Notterpek L, Lee HY et al (2004) The protooncogene Ski controls Schwann cell proliferation and myelination. Neuron 43:499–511PubMedCrossRef
12.
Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE (2001) Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 61:8074–8078PubMed
13.
Reed JA, Lin Q, Chen D, Mian IS, Medrano EE (2005) SKI pathways inducing progression of human melanoma. Cancer Metastasis Rev 24:265–272PubMedCrossRef
14.
Markowitz S, Wang J, Myeroff L et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338PubMedCrossRef
15.
Miyaki M, Iijima T, Konishi M et al (1999) Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18:3098–3103PubMedCrossRef
16.
Namciu S, Lyons GE, Micales BK et al (1995) Enhanced expression of mouse c-Ski accompanies terminal skeletal muscle differentiation in vivo and in vitro. Dev Dyn 204:291–300PubMedCrossRef
17.
Zhang F, Lundin M, Ristimäki A et al (2003) Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 63:5005–5010PubMed
18.
Fukuchi M, Nakajima M, Fukai Y et al (2004) Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer 108:818–824PubMedCrossRef
19.
Ritter M, Kattmann D, Teichler S et al (2006) Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia 20:437–443PubMedCrossRef
20.
Bravou V, Antonacopoulou A, Papadaki H et al (2009) TGF-beta repressors SnoN and Ski are implicated in human colorectal carcinogenesis. Cell Oncol 31:41–51PubMed
21.
Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700PubMedCrossRef
22.
23.
Boonmars T, Srisawangwong T, Srirach P et al (2007) Apoptosis-related gene expressions in hamsters re-infected with Opisthorchis viverrini and re-treated with praziquantel. Parasitol Res 102:57–62PubMedCrossRef
24.
Luo K (2004) Ski and SnoN: negative regulators of TGF-beta signaling. Curr Opin Genet Dev 14:65–70PubMedCrossRef
25.
Akiyoshi S, Inoue H, Hanai J et al (1999) c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem 274:35269–35277PubMedCrossRef
26.
Prunier C, Pessah M, Ferrand N et al (2003) The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation. J Biol Chem 278:26249–26257PubMedCrossRef
27.
Suzuki H, Yagi K, Kondo M et al (2004) c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad- binding elements. Oncogene 23:5068–5076PubMedCrossRef
28.
Zhang B, Halder SK, Zhang S, Datta PK (2009) Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 277:114–120PubMedCrossRef
29.
Patsenker E, Popov Y, Stickel F et al (2008) Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 135:660–670PubMedCrossRef
30.
Dumont N, Arteaga CL (2000) Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2:125–132PubMedCrossRef
31.
Milani S, Herbst H, Schuppan D, Stein H, Surrenti C (1991) Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 139:1221–1229PubMed
32.
Levy L, Hill CS (2006) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17:41–58PubMedCrossRef
33.
34.
Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25:435–457PubMedCrossRef
35.
Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J (1990) Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 62:175–185PubMedCrossRef
36.
Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257–261PubMedCrossRef
37.
Iavarone A, Massague J (1999) E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol 19:916–940PubMed
38.
Jang CW, Chen CH, Chen CC et al (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 4:51–58PubMedCrossRef
39.
Kim BG, Li C, Qiao W et al (2006) Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441:1015–1019PubMedCrossRef
40.
Kang YK, Kim WH, Jang JJ (2002) Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 33:877–883PubMedCrossRef
41.
Liu Y, Wang LF, Zou HF, Song XY, Xu HF, Lin P, Zheng HH, Yu XG (2006) Expression and location of Smad2, 4 mRNAs during and after liver fibrogenesis of rats. World J Gastroenterol 14;12(10):1577–1582
Metadata
Title
Involvement of c-Ski Oncoprotein in Carcinogenesis of Cholangiocacinoma Induced by Opisthorchis viverrini and N-nitrosodimethylamine
Authors
Thidarut Boonmars
Zhiliang Wu
Sirintip Boonjaruspinyo
Anucha Puapairoj
Butsara Kaewsamut
Isao Nagano
Somchai Pinlaor
Puangrat Yongvanit
Orasa Wonkchalee
Amornrat Juasook
Pakkayanee Sudsarn
Tuanchai Srisawangwong
Publication date
01-06-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9300-8

Other articles of this Issue 2/2011

Pathology & Oncology Research 2/2011 Go to the issue

Case Report

Malignancy or Inflammation? A Case Report of a Young Man with Fever of Unknown Origin

Research

Upregulation of Twist in Gastric Carcinoma Associated with Tumor Invasion and Poor Prognosis

Short Communication

Application of Linear Discriminant Analysis and Attenuated Total Reflectance Fourier Transform Infrared Microspectroscopy for Diagnosis of Colon Cancer

Research

Different Characteristics of Mitochondrial Microsatellite Instability Between Uterine Leiomyomas and Leiomyosarcomas

Research

Validation of Circulating MMP-7 Level as an Independent Prognostic Marker of Poor Survival in Urinary Bladder Cancer

Research

Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits